Marijn Storm, Katherine Wang, and Joshua R. Fattal published this article in Corporate Compliance Insights, which discusses the transformative impact of artificial intelligence on the life sciences industry. The article focuses particularly on drug discovery and personalized patient care, while highlighting the complex data privacy and security challenges faced by companies in the US and EU. It emphasizes key principles such as notice and choice, transparency, explainability, bias mitigation, individual rights, and data security that companies must navigate to comply with evolving regulations. The authors also address enforcement actions and provide strategic takeaways for companies to effectively leverage AI while ensuring compliance with relevant data privacy and security requirements.
Read the full article.
